GlassScriptPhysician profile
Charles C Boackle
NPI 1104935287
$10,131.34
in general payments reported to CMS, 2019-2025
47 companies · $642 in 2025
The $642 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,645 · 2020: $1,465 · 2021: $1,887 · 2022: $1,961 · 2023: $1,478 · 2024: $1,053 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,173.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $952.34 | 2019-2025 | |
| Lilly USA, LLC | $898.19 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $885.28 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $739.98 | 2021-2025 | Ubrelvy, Qulipta |
| Amarin Pharma, INC. | $699.30 | 2019-2022 | |
| Amgen INC. | $622.89 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Gilead Sciences, INC. | $579.70 | 2019-2024 | |
| Glaxosmithkline, LLC. | $413.42 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $381.66 | 2019-2021 | |
| Allergan, INC. | $338.02 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $298.85 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $286.95 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $258.07 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $222.37 | 2021-2023 | Freestyle Libre 2 |
| Eisai INC. | $219.70 | 2020-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Boackle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.